News & Publications

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

  • 01

    Jun

    22

  • KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion

  • 16

    May

    22

  • KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline

  • 12

    May

    22

  • KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates

  • 11

    May

    22

  • KemPharm to Present at Multiple Upcoming Investor Conferences

  • 05

    May

    22

  • KemPharm Announces Submission of Investigational New Drug Application for Phase 2 Trial of KP1077 in Idiopathic Hypersomnia (IH)

  • 04

    May

    22

  • KemPharm to Report First Quarter 2022 Financial Results

  • 19

    Apr

    22

  • KemPharm Doses First Subject in Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX)

  • 30

    Mar

    22

  • KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates

  • 24

    Mar

    22

  • KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference

  • 21

    Mar

    22

  • KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial

  • 16

    Mar

    22

  • KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)

  • 10

    Mar

    22

  • KemPharm to Report Fourth Quarter and Full-Year 2021 Results